MSD Doubles Biotech Production in the Netherlands

The company's Oss plant's expanded biotech production capacity can meet the growing global demand for cancer treatment.

MSD is the largest pharmaceutical company in the Netherlands and will double the biotech production capacity of Oss in the next few years. The US-based company said it needs to expand as global demand for MSD drugs continues to grow. With the increase in production capacity and the launch of new facilities, MSD is able to ship medicines from Oss to the rest of the world.

The investment in Oss is part of a $16 billion, multi-year MSD program designed to expand the company's manufacturing capabilities around the world. In the Netherlands, MSD's location in Haarlem, Oss and Boxmeer (Animal Health) is currently under construction.

Dutch attention to global cancer control

Cancer is one of the biggest challenges of our time. In the Netherlands, approximately 116,000 people develop cancer each year. About one in six people worldwide die from this disease.

MSD places great emphasis on immuno-oncology in its broad portfolio of oncology products. The MSD in the Netherlands, especially the MSD of Oss, has been closely involved in the invention of MSD immuno-oncology products, and this important role has continued in the biotechnology production and manufacturing process.

John Glavas, director of MSD Oss Biotech, said: "With the new high-tech facilities and higher manufacturing capabilities, the Netherlands will make an important contribution to our company's commitment to oncology and new innovations for cancer patients." Our employees are proud of their passion and pride in these therapies every day. Expansion is also an important step for BV Nederland. MSD currently has 6,000 employees in the Netherlands and is active in the areas of development, clinical research, production, packaging and distribution.

MSD has been a key player in the Dutch life sciences & health sector since 1954.

Source: MSD press release [Dutch only]